scholarly journals Enalapril in therapy of arterial hypertension in patients with juvenile obesity

1994 ◽  
Vol 40 (6) ◽  
pp. 25-26 ◽  
Author(s):  
Ye. V. Malyghina ◽  
G. A. Gherasimov ◽  
T. M. Atamanova
Keyword(s):  
Arterial Hypertension ◽  
Enzyme Inhibitors ◽  
Plasma Renin ◽  
Blood Lipid ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Hypotensive Effect ◽  
Negative Effects ◽  
Converting Enzyme Inhibitors ◽  
Drug Of Choice ◽  
Juvenile Obesity

Clinical efficacy of enalapril, a drug belonging to a group of angiotensin-converting enzyme inhibitors, was studied in patients with pubertal juvenile dyspituitarism (juvenile obesity) coursing with arterial hypertension. A reactive increase of plasma renin activity and reduced concentration of plasma aldosterone were revealed. The drug was characterized by a pronounced hypotensive effect. No negative effects on the blood lipid spectrum or carbohydrate metabolism were observed. The study showed that enalapril may be a drug of choice in the treatment of the hypertensive syndrome in patients with juvenile obesity.

scholarly journals Atrial fibrillation and arterial hypertension

2011 ◽  
Vol 17 (4) ◽  
pp. 293-304
Author(s):  
E. I. Baranova
Keyword(s):  
Atrial Fibrillation ◽  
Arterial Hypertension ◽  
Enzyme Inhibitors ◽  
Anticoagulation Therapy ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Angiotensin Ii Receptor ◽  
Primary And Secondary Prevention ◽  
Converting Enzyme Inhibitors ◽  
Receptor Blockers

Review deals with atrial fibrillation and arterial hypertension. Possible pathological mechanisms of atrial fibrillation due to hypertension include haemodynamic effects, structural and electrophysiological heart remodeling partly connected with activation of renin-angiotensin-aldosterone system. Problems of primary and secondary prevention of atrial fibrillation in hypertensive patients are discussed, particularly the role of antihypertensive treatment including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Risk stratification for stroke and thromboembolism and anticoagulation therapy are discussed.

scholarly journals Atrial fibrillation and arterial hypertension

2011 ◽  
Vol 17 (4) ◽  
pp. 293-304 ◽  
Author(s):  
E. I. Baranova
Keyword(s):  
Atrial Fibrillation ◽  
Arterial Hypertension ◽  
Enzyme Inhibitors ◽  
Anticoagulation Therapy ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Angiotensin Ii Receptor ◽  
Primary And Secondary Prevention ◽  
Converting Enzyme Inhibitors ◽  
Receptor Blockers

Review deals with atrial fibrillation and arterial hypertension. Possible pathological mechanisms of atrial fibrillation due to hypertension include haemodynamic effects, structural and electrophysiological heart remodeling partly connected with activation of renin-angiotensin-aldosterone system. Problems of primary and secondary prevention of atrial fibrillation in hypertensive patients are discussed, particularly the role of antihypertensive treatment including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Risk stratification for stroke and thromboembolism and anticoagulation therapy are discussed.

Reduction of blood pressure fluctuations by telmisartan molecule especially in combination with calcium channel antagonist

2021 ◽  
Vol 14 (4) ◽  
pp. 410-416
Author(s):  
Maria Łukasiewicz ◽  
Artur Mamcarz
Keyword(s):  
Enzyme Inhibitors ◽  
Pressure Fluctuations ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Hypotensive Effect ◽  
Good Alternative ◽  
Converting Enzyme Inhibitors ◽  
Once Daily ◽  
Smoothness Index ◽  
High Smoothness ◽  
Single Pill

1.28 billion people suffer from hypertension, and its complications cause 10 million deaths each year. Effective antihypertensive therapy is therefore one of the priority tasks of health care. Achieving good BP control depends on many factors, but one of the primary ones is the use of maximally effective therapy in the simplest possible regimen. Amlodipine in combination with telmisartan in the single-pill combination, through its high smoothness index, makes it possible to achieve a satisfactory hypotensive effect lasting 24 h when taken once daily. This combination is also a good alternative for cardiovascularly burdened patients who cannot use angiotensin-converting enzyme inhibitors and for elderly patients, especially after stroke

scholarly journals Initiation and Single Dispensing in Cardiovascular and Insulin Medications: Prevalence and Explanatory Factors

2020 ◽  
Vol 17 (10) ◽  
pp. 3358
Author(s):  
Carles Vilaplana-Carnerero ◽  
Ignacio Aznar-Lou ◽  
María Teresa Peñarrubia-María ◽  
Antoni Serrano-Blanco ◽  
Rita Fernández-Vergel ◽  
...  
Keyword(s):  
Enzyme Inhibitors ◽  
Platelet Aggregation Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Negative Effects ◽  
Real World Data ◽  
Converting Enzyme Inhibitors ◽  
Explanatory Factors ◽  
Aggregation Inhibitors ◽  
Place Of Origin

Background: Adherence problems have negative effects on health, but there is little information on the magnitude of non-initiation and single dispensing. Objective: The aim of this study was to estimate the prevalence of non-initiation and single dispensation and identify associated predictive factors for the main treatments prescribed in Primary Care (PC) for cardiovascular disease (CVD) and diabetes. Methods: Cohort study with real-world data. Patients who received a first prescription (2013–2014) for insulins, platelet aggregation inhibitors, angiotensin-converting enzyme inhibitors (ACEI) or statins in Catalan PC were included. The prevalence of non-initiation and single dispensation was calculated. Factors that explained these behaviours were explored. Results: At three months, between 5.7% (ACEI) and 9.1% (antiplatelets) of patients did not initiate their treatment and between 10.6% (statins) and 18.4% (ACEI) filled a single prescription. Body mass index, previous CVD, place of origin and having a substitute prescriber, among others, influenced the risk of non-initiation and single dispensation. Conclusions: The prevalence of non-initiation and single dispensation of CVD medications and insulin prescribed in PC in is high. Patient and health-system factors, such as place of origin and type of prescriber, should be taken into consideration when prescribing new medications for CVD and diabetes.

scholarly journals AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND CALCIUM ANTAGONIST COMBINATION IN PHARMACOTHERAPY OF ARTERIAL HYPERTENSION

2014 ◽  
Vol 13 (1) ◽  
pp. 64-68
Author(s):  
L. L. Kirichenko ◽  
S. V. Gatsura ◽  
A. N. Golosova ◽  
K. V. Ovsyannikov ◽  
O. V. Budik ◽  
...  
Keyword(s):  
Calcium Antagonist ◽  
Endothelial Dysfunction ◽  
Combination Therapy ◽  
Angiotensin Converting Enzyme ◽  
Arterial Hypertension ◽  
Enzyme Inhibitors ◽  
Enzyme Inhibitor ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors

The paper focuses on the justification for preferential administration of antihypertensive combination therapy. Pharmacotherapeutic features of starting the treatment with a combination of angiotensin-converting enzyme inhibitors (ACEI) and calcium antagonists (AC) are reviewed. The authors also present the latest evidence on the ACEI/AC combination effects on such vascular parameters as microcirculation and endothelial dysfunction.

scholarly journals Arterial hypertension and metabolic syndrome: specifics of antihypertensive therapy

2011 ◽  
Vol 10 (4) ◽  
pp. 107-109
Author(s):  
L. I. Abasova ◽  
R. L. Dashdamirov ◽  
A. B. Bakhshaliev
Keyword(s):  
Metabolic Syndrome ◽  
Arterial Hypertension ◽  
Metabolic Profile ◽  
Enzyme Inhibitors ◽  
Antihypertensive Agents ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Randomised Trials ◽  
Converting Enzyme Inhibitors ◽  
Literature Evidence

This review summarizes the literature evidence on humoral disturbances in arterial hypertension (AH), as well as on AH interrelationship with individual components of metabolic syndrome (MS). Based on the results of multi-centre randomised trials, the rationale for the use of antihypertensive agents with favourable metabolic profile is demonstrated, in particular, for antagonists of slow calcium channels, angiotensin-converting enzyme inhibitors, and selective imidazoline receptor agonists.

Sign in / Sign up

Export Citation Format

Share Document